{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:37:00Z","timestamp":1784057820650,"version":"3.55.0"},"reference-count":214,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:p>Invariant Natural Killer T cell therapy is an emerging platform of immunotherapy for cancer treatment. This unique cell population is a promising candidate for cell therapy for cancer treatment because of its inherent cytotoxicity against CD1d positive cancers as well as its ability to induce host CD8 T cell cross priming. Substantial evidence supports that iNKT cells can modulate myelomonocytic populations in the tumor microenvironment to ameliorate immune dysregulation to antagonize tumor progression. iNKT cells can also protect from graft-versus-host disease (GVHD) through several mechanisms, including the expansion of regulatory T cells (Treg). Ultimately, iNKT cell-based therapy can retain antitumor activity while providing protection against GVHD simultaneously. Therefore, these biological properties render iNKT cells as a promising \u201coff-the-shelf\u201d therapy for diverse hematological malignancies and possible solid tumors. Further the introduction of a chimeric antigen recetor (CAR) can further target iNKT cells and enhance function. We foresee that improved vector design and other strategies such as combinatorial treatments with small molecules or immune checkpoint inhibitors could improve CAR iNKT <jats:italic>in vivo<\/jats:italic> persistence, functionality and leverage anti-tumor activity along with the abatement of iNKT cell dysfunction or exhaustion.<\/jats:p>","DOI":"10.3389\/frtra.2024.1353803","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T04:49:06Z","timestamp":1714970946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies"],"prefix":"10.3389","volume":"3","author":[{"given":"Chaiyaporn","family":"Boonchalermvichian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biki","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2022.897750","article-title":"Adoptive immunotherapy with engineered iNKT cells to target cancer cells and the suppressive microenvironment","volume":"9","author":"Delfanti","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1182\/blood-2014-05-576017","article-title":"CD4\u2009+\u2009invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4\u2009+\u2009CD25\u2009+\u2009FoxP3\u2009+\u2009regulatory T cells","volume":"124","author":"Schneidawind","year":"2014","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101342","DOI":"10.1016\/j.tranon.2022.101342","article-title":"iNKT: a new avenue for CAR-based cancer immunotherapy","volume":"17","author":"Liu","year":"2022","journal-title":"Transl Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1172\/JCI83476","article-title":"CD62l+ NKT cells have prolonged persistence and antitumor activity in vivo","volume":"126","author":"Tian","year":"2016","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.4049\/jimmunol.1800429","article-title":"IL-21 selectively protects CD62l+ NKT cells and enhances their effector functions for adoptive immunotherapy","volume":"201","author":"Ngai","year":"2018","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1111\/cas.14428","article-title":"Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner","volume":"111","author":"Aoki","year":"2020","journal-title":"Cancer Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","article-title":"Allogeneic CAR-invariant natural killer T cells exert potent antitumor effects through host CD8 T cell cross-priming","volume":"27","author":"Simonetta","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fimmu.2018.00384","article-title":"Novel approaches to exploiting invariant NKT cells in cancer immunotherapy","volume":"9","author":"Wolf","year":"2018","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1084\/jem.188.8.1521","article-title":"CD1d-mediated recognition of an \u03b1-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution","volume":"188","author":"Brossay","year":"1998","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1084\/jem.192.5.741","article-title":"Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers","volume":"192","author":"Matsuda","year":"2000","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1084\/jem.191.11.1895","article-title":"In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers","volume":"191","author":"Benlagha","year":"2000","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1471-4906(03)00179-0","article-title":"Evolutionary constraints on CD1 structure: insights from comparative genomic analysis","volume":"24","author":"Dascher","year":"2003","journal-title":"Trends Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1038\/s41467-020-20073-8","article-title":"Thymic iNKT single cell analyses unmask the common developmental program of mouse innate T cells","volume":"11","author":"Harsha Krovi","year":"2020","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1126\/science.1216557","article-title":"Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis","volume":"335","author":"Yuan","year":"2012","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.4049\/jimmunol.0901059","article-title":"Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions","volume":"183","author":"Doisne","year":"2009","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1084\/jem.20011786","article-title":"Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining","volume":"195","author":"Gumperz","year":"2002","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20011908","article-title":"Distinct functional lineages of human V(alpha)24 natural killer T cells","volume":"195","author":"Lee","year":"2002","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02647.x","article-title":"Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11","volume":"122","author":"Montoya","year":"2007","journal-title":"Immunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/eji.200939349","article-title":"Invariant NKT cells and CD1d+ cells amass in human omentum and are depleted in patients with cancer and obesity","volume":"39","author":"Lynch","year":"2009","journal-title":"Eur J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nature03407","article-title":"Recognition of bacterial glycosphingolipids by natural killer T cells","volume":"434","author":"Kinjo","year":"2005","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ni1380","article-title":"Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria","volume":"7","author":"Kinjo","year":"2006","journal-title":"Nat Immunol"},{"key":"B25","first-page":"643","article-title":"Worth holding on to","volume":"11","author":"Bordon","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature03408","article-title":"Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections","volume":"434","author":"Mattner","year":"2005","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1021\/jm00012a018","article-title":"Structure-activity relationship of.alpha.-galactosylceramides against B16-bearing mice","volume":"38","author":"Morita","year":"1995","journal-title":"J Med Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.clim.2010.11.010","article-title":"Clinical experience with \u03b1-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B\/C infection","volume":"140","author":"Schneiders","year":"2011","journal-title":"Clin Immunol"},{"key":"B29","first-page":"3702","article-title":"A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors","volume":"8","author":"Giaccone","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/bloodadvances.2020003272","article-title":"Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD","volume":"5","author":"Hirai","year":"2021","journal-title":"Blood Advances"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/eji.201546114","article-title":"Non-glycosidic compounds can stimulate both human and mouse i NKT cells","volume":"46","author":"Jukes","year":"2016","journal-title":"Eur J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1200\/JCO.2022.40.16_suppl.2582","article-title":"A phase 1 first-in-human dose finding\/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non\u2013small cell lung cancer (NSCLC; IMP-MEL)","volume":"40","author":"Coupe","year":"2022","journal-title":"JCO"},{"key":"B33","year":""},{"key":"B34","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.4049\/jimmunol.1401805","article-title":"Role and regulation of CD1d in normal and pathological B cells","volume":"193","author":"Chaudhry","year":"2014","journal-title":"J Immunol"},{"key":"B35","year":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1365-2567.2000.00001.x","article-title":"CD1d Structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes","volume":"100","author":"Exley","year":"2000","journal-title":"Immunology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood.2022016201","article-title":"Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy","volume":"141","author":"Courtney","year":"2023","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1309\/AJCP2F2DOXOTXHZA","article-title":"The diagnostic value of CD1d expression in a large cohort of patients with B-cell chronic lymphoproliferative disorders","volume":"136","author":"Kotsianidis","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/sj.leu.2402943","article-title":"Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells","volume":"17","author":"Metelitsa","year":"2003","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3389\/fimmu.2017.01355","article-title":"Invariant natural killer T cells in immune regulation of blood cancers: harnessing their potential in immunotherapies","volume":"8","author":"Lam","year":"2017","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.21378.1","article-title":"Recent advances in iNKT cell development","volume":"9","author":"Hogquist","year":"2020","journal-title":"F1000Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood.2021010887","article-title":"Invariant natural killer T-cell subsets have diverse graft-versus-host-disease\u2013preventing and antitumor effects","volume":"138","author":"Maas-Bauer","year":"2021","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3389\/fimmu.2018.01393","article-title":"Invariant natural killer T cell subsets\u2014more than just developmental intermediates","volume":"9","author":"Krovi","year":"2018","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/ni.3437","article-title":"Innate-like functions of natural killer T cell subsets result from highly divergent gene programs","volume":"17","author":"Engel","year":"2016","journal-title":"Nat Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2015.06.025","article-title":"Tissue specific distribution of iNKT cells impacts their cytokine response","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41577-018-0034-2","article-title":"Tissue-specific functions of invariant natural killer T cells","volume":"18","author":"Crosby","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1084\/jem.20050456","article-title":"Characterization of the early stages of thymic NKT cell development","volume":"202","author":"Benlagha","year":"2005","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2016.01.001","article-title":"Development of invariant natural killer T cells","volume":"39","author":"Gapin","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.molimm.2018.09.023","article-title":"The ins and outs of type I iNKT cell development","volume":"105","author":"Shissler","year":"2019","journal-title":"Mol Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3389\/fimmu.2017.01950","article-title":"Unraveling natural killer T-cells development","volume":"8","author":"Bennstein","year":"2018","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ni.1641","article-title":"The BTB-zinc finger transcriptional regulator, PLZF, controls the development of iNKT cell effector functions","volume":"9","author":"Kovalovsky","year":"2008","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.immuni.2008.07.011","article-title":"The transcription factor PLZF (Zbtb16) directs the effector program of the NKT cell lineage","volume":"29","author":"Savage","year":"2008","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1001255","DOI":"10.1371\/journal.pbio.1001255","article-title":"Development and function of invariant natural killer T cells producing TH2- and TH17-cytokines","volume":"10","author":"Watarai","year":"2012","journal-title":"PLoS Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev.immunol.21.120601.141057","article-title":"The regulatory role of V\u03b114 NKT cells in innate and acquired immune response","volume":"21","author":"Taniguchi","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1146\/annurev.immunol.22.012703.104608","article-title":"CD1: antigen presentation and T cell function","volume":"22","author":"Brigl","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT Cells: what\u2019s in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1600-065X.2012.01166.x","article-title":"Molecular basis of lipid antigen presentation by CD 1d and recognition by natural killer T cells","volume":"250","author":"Girardi","year":"2012","journal-title":"Immunol Rev"},{"key":"B59","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1126\/science.1092009","article-title":"Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins","volume":"303","author":"Zhou","year":"2004","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/nature04001","article-title":"Apolipoprotein-mediated pathways of lipid antigen presentation","volume":"437","author":"van den Elzen","year":"2005","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1172\/JCI40451","article-title":"Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice","volume":"120","author":"Freigang","year":"2010","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1126\/science.291.5504.664","article-title":"Glycolipid antigen processing for presentation by CD1d molecules","volume":"291","author":"Prigozy","year":"2001","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1126\/science.1115301","article-title":"Assistance of microbial glycolipid antigen processing by CD1e","volume":"310","author":"de la Salle","year":"2005","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1016\/S0040-4020(01)86991-X","article-title":"Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus","volume":"50","author":"Natori","year":"1994","journal-title":"Tetrahedron"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","article-title":"CD1d-restricted And TCR-mediated activation of valpha14 NKT cells by glycosylceramides","volume":"278","author":"Kawano","year":"1997","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.1073\/pnas.95.10.5690","article-title":"Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V\u03b114 NKT cells","volume":"95","author":"Kawano","year":"1998","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B67","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2567.2004.02111.x","article-title":"Natural killer T-cell populations in C57BL\/6 and NK1.1 congenic BALB.NK mice\u2014a novel thymic subset defined in BALBNK mice","volume":"114","author":"Stenstr\u00f6m","year":"2005","journal-title":"Immunology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev-immunol-101819-074948","article-title":"Natural killer cells: from innate to adaptive features","volume":"39","author":"Mujal","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"8395","DOI":"10.1073\/pnas.1332805100","article-title":"Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.4049\/jimmunol.174.7.3864","article-title":"Cutting edge: IFN-gamma signaling to macrophages is required for optimal Valpha14i NK T\/NK cell cross-talk","volume":"174","author":"Wesley","year":"2005","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1146\/annurev.immunol.23.021704.115742","article-title":"Toward an understanding of NKT cell biology: progress and paradoxes","volume":"23","author":"Kronenberg","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/eji.200526157","article-title":"Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells","volume":"35","author":"Sriram","year":"2005","journal-title":"Eur J Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ni827","article-title":"Prolonged IFN-\u03b3\u2013producing NKT response induced with \u03b1-galactosylceramide\u2013loaded DCs","volume":"3","author":"Fujii","year":"2002","journal-title":"Nat Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.it.2019.09.008","article-title":"Immune networks and therapeutic targeting of iNKT cells in cancer","volume":"40","author":"Fujii","year":"2019","journal-title":"Trends Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1172\/JCI24762","article-title":"Glycolipid antigen induces long-term natural killer T cell anergy in mice","volume":"115","author":"Parekh","year":"2005","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-immunol-032713-120243","article-title":"Biology of CD1- and MR1-restricted T cells","volume":"32","author":"Salio","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1084\/jem.20030630","article-title":"Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function","volume":"198","author":"Stetson","year":"2003","journal-title":"J Exp Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.4049\/jimmunol.163.11.5871","article-title":"A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement","volume":"163","author":"Leite-De-Moraes","year":"1999","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4049\/jimmunol.2000870","article-title":"The invariant NKT cell response has differential signaling requirements during antigen-dependent and antigen-independent activation","volume":"206","author":"Anderson","year":"2021","journal-title":"J Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e1000106","DOI":"10.1371\/journal.ppat.1000106","article-title":"NK cell-like behavior of valpha14i NK T cells during MCMV infection","volume":"4","author":"Wesley","year":"2008","journal-title":"PLoS Pathog"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.4049\/jimmunol.181.7.4452","article-title":"Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals","volume":"181","author":"Tyznik","year":"2008","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clim.2011.04.017","article-title":"Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects","volume":"140","author":"Exley","year":"2011","journal-title":"Clin Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.4049\/jimmunol.0802492","article-title":"Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides","volume":"182","author":"Paget","year":"2009","journal-title":"J Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.4049\/jimmunol.178.5.2706","article-title":"Invariant NKT cells amplify the innate immune response to lipopolysaccharide","volume":"178","author":"Nagarajan","year":"2007","journal-title":"J Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/eji.200838575","article-title":"The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production","volume":"39","author":"Bourgeois","year":"2009","journal-title":"Eur J Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1099529","DOI":"10.3389\/fimmu.2023.1099529","article-title":"Early activation and recruitment of invariant natural killer T cells during liver ischemia-reperfusion: the major role of the alarmin interleukin-33","volume":"14","author":"Robin","year":"2023","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fimmu.2017.00570","article-title":"Reciprocal crosstalk between dendritic cells and natural killer T cells: mechanisms and therapeutic potential","volume":"8","author":"Keller","year":"2017","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1038\/emboj.2012.87","article-title":"The location of splenic NKT cells favours their rapid activation by blood-borne antigen: NKT cells are activated outside splenic white pulp","volume":"31","author":"Barral","year":"2012","journal-title":"EMBO J"},{"key":"B90","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.immuni.2013.12.004","article-title":"A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens","volume":"40","author":"Arora","year":"2014","journal-title":"Immunity"},{"key":"B91","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.immuni.2007.08.017","article-title":"Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids","volume":"27","author":"Paget","year":"2007","journal-title":"Immunity"},{"key":"B92","doi-asserted-by":"publisher","first-page":"20490","DOI":"10.1073\/pnas.0710145104","article-title":"Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation","volume":"104","author":"Salio","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1084\/jem.20102555","article-title":"Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection","volume":"208","author":"Brigl","year":"2011","journal-title":"J Exp Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1084\/jem.20040317","article-title":"The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80\/86 costimulation","volume":"199","author":"Fujii","year":"2004","journal-title":"J Exp Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.4049\/jimmunol.163.9.4647","article-title":"Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells","volume":"163","author":"Carnaud","year":"1999","journal-title":"J Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T cells by \u03b1-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J Exp Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/ni.1848","article-title":"Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell\u2013licensed DCs","volume":"11","author":"Semmling","year":"2010","journal-title":"Nat Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.3389\/fimmu.2018.02375","article-title":"The pathophysiological relevance of the iNKT cell\/mononuclear phagocyte crosstalk in tissues","volume":"9","author":"Cortesi","year":"2018","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.celrep.2018.02.058","article-title":"Bimodal CD40\/fas-dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression","volume":"22","author":"Cortesi","year":"2018","journal-title":"Cell Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1073\/pnas.0408288102","article-title":"Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion","volume":"102","author":"Schmieg","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B101","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/ni.1853","article-title":"CD169(+) macrophages Present lipid antigens to mediate early activation of iNKT cells in lymph nodes","volume":"11","author":"Barral","year":"2010","journal-title":"Nat Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1146\/annurev-immunol-032414-112220","article-title":"CD1d-Restricted and TCR-mediated activation of V\u03b114 NKT cells by glycosylceramides","volume":"33","author":"Varol","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"22262","DOI":"10.1073\/pnas.1910412116","article-title":"Myeloid cells activate iNKT cells to produce IL-4 in the thymic medulla","volume":"116","author":"Wang","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B104","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41590-021-00934-0","article-title":"Embryonic macrophages function during early life to determine invariant natural killer T cell levels at barrier surfaces","volume":"22","author":"Gensollen","year":"2021","journal-title":"Nat Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"24378","DOI":"10.1074\/jbc.M112.371807","article-title":"Short term high fat diet challenge promotes alternative macrophage polarization in adipose tissue via natural killer T cells and interleukin-4","volume":"287","author":"Ji","year":"2012","journal-title":"J Biol Chem"},{"key":"B106","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.immuni.2012.06.016","article-title":"Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production","volume":"37","author":"Lynch","year":"2012","journal-title":"Immunity"},{"key":"B107","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clim.2010.10.005","article-title":"Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans","volume":"140","author":"Metelitsa","year":"2011","journal-title":"Clin Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","article-title":"Targeting natural killer cells and natural killer T cells in cancer","volume":"12","author":"Vivier","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"11287","DOI":"10.1073\/pnas.0801631105","article-title":"Diverse cytokine production by NKT cell subsets and identification of an IL-17\u2013producing CD4\u2212NK1.1\u2212NKT cell population","volume":"105","author":"Coquet","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.4049\/jimmunol.160.7.3121","article-title":"CD1.1 Expression by mouse antigen-presenting cells and marginal zone B cells","volume":"160","author":"Roark","year":"1998","journal-title":"J Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"8339","DOI":"10.1073\/pnas.0801375105","article-title":"NK T cells provide lipid antigen-specific cognate help for B cells","volume":"105","author":"Leadbetter","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B112","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood-2008-06-166249","article-title":"NKT-cell help to B lymphocytes can occur independently of cognate interaction","volume":"113","author":"Tonti","year":"2009","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"12474","DOI":"10.1073\/pnas.1504790112","article-title":"Cognate interaction with iNKT cells expands IL-10-producing B regulatory cells","volume":"112","author":"Vomhof-DeKrey","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B114","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1084\/jem.20021293","article-title":"Prevention of arthritis by interleukin 10-producing B cells","volume":"197","author":"Mauri","year":"2003","journal-title":"J Exp Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41467-018-02911-y","article-title":"CD1d-dependent Immune suppression mediated by regulatory B cells through modulations of iNKT cells","volume":"9","author":"Oleinika","year":"2018","journal-title":"Nat Commun"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/rheumatology\/keq457","article-title":"Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity","volume":"50","author":"Cho","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nm0602-588","article-title":"CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung","volume":"8","author":"Nieuwenhuis","year":"2002","journal-title":"Nat Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1002\/eji.200324254","article-title":"Critical role of V\u03b114+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection","volume":"33","author":"Kawakami","year":"2003","journal-title":"Eur J Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1084\/jem.20061097","article-title":"Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation","volume":"203","author":"Lappas","year":"2006","journal-title":"J Exp Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/hep.26471","article-title":"Invariant NKT cell activation induces neutrophil accumulation and hepatitis: opposite regulation by IL-4 and IFN-\u03b3: hepatology","volume":"58","author":"Wang","year":"2013","journal-title":"Hepatology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.4049\/jimmunol.1101273","article-title":"Neutrophilic granulocytes modulate invariant NKT cell function in mice and humans","volume":"188","author":"Wingender","year":"2012","journal-title":"Journal Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.cyto.2010.04.016","article-title":"Cytokine dependent and independent iNKT cell activation","volume":"51","author":"Reilly","year":"2010","journal-title":"Cytokine"},{"key":"B123","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/SHK.0000000000000553","article-title":"Effect of PD-1: PD-L1 in invariant natural killer T-cell emigration and chemotaxis following sepsis","volume":"45","author":"Young","year":"2016","journal-title":"Shock"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/eji.200737838","article-title":"Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells","volume":"38","author":"Liu","year":"2008","journal-title":"Eur J Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2009-02-205492","article-title":"NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-\u03b3 and CXCR3 chemokines","volume":"114","author":"Wallace","year":"2009","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.03.002","article-title":"Targeting iNKT cells for the treatment of sickle cell disease","volume":"140","author":"Field","year":"2011","journal-title":"Clin Immunol"},{"key":"B127","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2904","article-title":"Presumed guilty: natural killer T cell defects and human disease","volume":"12","author":"Berzins","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","article-title":"Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Chaidos","year":"2012","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/sj.bmt.1704582","article-title":"Recovery of V\u03b124+ NKT cells after hematopoietic stem cell transplantation","volume":"34","author":"Haraguchi","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B130","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/bmt.2015.335","article-title":"Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression","volume":"51","author":"Guan","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B131","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.4049\/jimmunol.1003748","article-title":"Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+\u2009and CD4\u2212 subset dynamics and correlates with remission state","volume":"186","author":"de Lalla","year":"2011","journal-title":"J Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e27440","DOI":"10.4161\/onci.27440","article-title":"Invariant NKT cells: killers and conspirators against cancer","volume":"2","author":"Bassiri","year":"2013","journal-title":"Oncoimmunology"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.4049\/jimmunol.1001018","article-title":"Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95\/CD178-dependent and is correlated with antigenic potency","volume":"185","author":"Wingender","year":"2010","journal-title":"J Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1182\/blood-2005-08-3103","article-title":"T-bet concomitantly controls migration, survival, and effector functions during the development of V\u03b114i NKT cells","volume":"107","author":"Matsuda","year":"2006","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.4049\/jimmunol.161.5.2217","article-title":"IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells1","volume":"161","author":"Dao","year":"1998","journal-title":"J Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1182\/blood.V97.7.2067","article-title":"TRAIL expression by activated human CD4+\u2009V\u03b124NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells","volume":"97","author":"Nieda","year":"2001","journal-title":"Blood"},{"key":"B137","year":""},{"key":"B138","doi-asserted-by":"publisher","first-page":"e65075","DOI":"10.1371\/journal.pone.0065075","article-title":"Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model","volume":"8","author":"Nur","year":"2013","journal-title":"PloS One"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e20702","DOI":"10.1371\/journal.pone.0020702","article-title":"CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis","volume":"6","author":"Hix","year":"2011","journal-title":"PloS One"},{"key":"B140","doi-asserted-by":"publisher","first-page":"eabn6563","DOI":"10.1126\/sciimmunol.abn6563","article-title":"TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells","volume":"7","author":"Delfanti","year":"2022","journal-title":"Sci Immunol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/blood-2016-11-751065","article-title":"Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis","volume":"129","author":"Gorini","year":"2017","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.702726","article-title":"Regulatory T cells: barriers of immune infiltration into the tumor microenvironment","volume":"12","author":"Scott","year":"2021","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukocyte Biol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","article-title":"Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia","volume":"99","author":"Tsukada","year":"2002","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","first-page":"e11311","DOI":"10.1371\/journal.pone.0011311","article-title":"Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide","volume":"5","author":"Nowak","year":"2010","journal-title":"PloS One"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"B147","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-3-319-50026-3_11","article-title":"Graft-Versus-Host disease (GvHD)","volume-title":"The European blood and marrow transplantation textbook for nurses: Under the auspices of EBMT","author":"Murray","year":"2018"},{"key":"B148","doi-asserted-by":"publisher","first-page":"715424","DOI":"10.3389\/fimmu.2021.715424","article-title":"The pathophysiology and treatment of graft-versus-host disease: lessons learnt from animal models","volume":"12","author":"Teshima","year":"2021","journal-title":"Front Immunol"},{"key":"B149","first-page":"90","article-title":"Targeting cytokines in GVHD therapy","volume":"2","author":"Kumar","year":"2017","journal-title":"J Immunol Res Therapy"},{"key":"B150","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1182\/blood-2014-11-612762","article-title":"Third-party CD4\u2009+\u2009invariant natural killer T cells protect from murine GVHD lethality","volume":"125","author":"Schneidawind","year":"2015","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3389\/fimmu.2017.00900","article-title":"Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Mavers","year":"2017","journal-title":"Front Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41409-019-0600-7","article-title":"Immune regulation in hematopoietic cell transplantation","volume":"54","author":"Negrin","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20042592","article-title":"Sustained expansion of NKT cells and antigen-specific T cells after injection of \u03b1-galactosyl-ceramide loaded mature dendritic cells in cancer patients","volume":"201","author":"Chang","year":"2005","journal-title":"J Exp Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clim.2011.01.009","article-title":"Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer","volume":"140","author":"Motohashi","year":"2011","journal-title":"Clin Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/hep.21447","article-title":"Intrahepatic delivery of \u03b1-galactosylceramide-pulsed dendritic cells suppresses liver tumor","volume":"45","author":"Tatsumi","year":"2007","journal-title":"Hepatology"},{"key":"B156","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12967-017-1219-3","article-title":"Dendritic cells combined with tumor cells and \u03b1-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma","volume":"15","author":"Escrib\u00e0-Garcia","year":"2017","journal-title":"J Transl Med"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1084\/jem.20070458","article-title":"Cross-presentation of glycolipid from tumor cells loaded with \u03b1-galactosylceramide leads to potent and long-lived T cell\u2013mediated immunity via dendritic cells","volume":"204","author":"Shimizu","year":"2007","journal-title":"J Exp Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"11252","DOI":"10.1073\/pnas.0604812103","article-title":"Glycolipid \u03b1-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice","volume":"103","author":"Fujii","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B159","doi-asserted-by":"publisher","first-page":"e990793","DOI":"10.4161\/2162402X.2014.990793","article-title":"NKT cell-targeted vaccination plus anti-4\u20131BB antibody generates persistent CD8 T cell immunity against B cell lymphoma","volume":"4","author":"Kobayashi","year":"2015","journal-title":"OncoImmunology"},{"key":"B160","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1182\/blood-2012-04-426643","article-title":"NKT Cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma","volume":"120","author":"Mattarollo","year":"2012","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1182\/blood-2014-04-568956","article-title":"An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment","volume":"124","author":"Gibbins","year":"2014","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B164","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, A first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"The Lancet Haematology"},{"key":"B165","author":"Xu","year":""},{"key":"B166","year":""},{"key":"B167","year":""},{"key":"B168","year":""},{"key":"B169","year":""},{"key":"B170","author":"Ramos","year":""},{"key":"B171","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI42027","article-title":"Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells","volume":"120","author":"Watarai","year":"2010","journal-title":"J Clin Invest"},{"key":"B172","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.3390\/cells10123497","article-title":"Development of stem cell-derived immune cells for off-the-shelf cancer immunotherapies","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"B173","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ijms22031096","article-title":"Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma","volume":"22","author":"Poels","year":"2021","journal-title":"IJMS"},{"key":"B175","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/35040504","article-title":"Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function","volume":"408","author":"Parrish-Novak","year":"2000","journal-title":"Nature"},{"key":"B176","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.4049\/jimmunol.178.5.2827","article-title":"IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production1","volume":"178","author":"Coquet","year":"2007","journal-title":"J Immunol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"8725","DOI":"10.1021\/bi0202023","article-title":"The common \u03b3 chain (\u03b3c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3","volume":"41","author":"Habib","year":"2002","journal-title":"Biochemistry"},{"key":"B178","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1182\/bloodadvances.2023010032","article-title":"Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7hyFc","volume":"7","author":"O'Neal","year":"2023","journal-title":"Blood Advances"},{"key":"B179","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/2326-6066.CIR-19-0134","article-title":"A high-avidity T-cell receptor redirects natural killer T-cell specificity and outcompetes the endogenous invariant T-cell receptor","volume":"8","author":"Landoni","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B180","doi-asserted-by":"publisher","first-page":"744823","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B181","first-page":"669","article-title":"FDA Approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B182","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","article-title":"The next-generation CAR-T therapy landscape","volume":"22","author":"Verma","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B183","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"B184","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B187","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B189","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","article-title":"Current perspectives on mesenchymal stromal cell therapy for graft versus host disease","volume":"20","author":"Kadri","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease biology, prevention and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"B191","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-refractory chronic graft-versus-host disease: treatment options and patient management","volume":"56","author":"Wolff","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B192","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41409-022-01881-6","article-title":"Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the transplant complications working party of the EBMT","volume":"58","author":"Moiseev","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B193","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1083-8791(03)00108-3","article-title":"Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells","volume":"9","author":"Lan","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"B194","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.4049\/jimmunol.178.10.6242","article-title":"Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow Transplantation1","volume":"178","author":"Pillai","year":"2007","journal-title":"J Immunol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood-2010-08-303008","article-title":"Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4\u2013dependent mechanism","volume":"117","author":"Leveson-Gower","year":"2011","journal-title":"Blood"},{"key":"B196","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4049\/jimmunol.174.1.551","article-title":"Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T Cells1","volume":"174","author":"Hashimoto","year":"2005","journal-title":"J Immunol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.bbmt.2010.11.022","article-title":"Pharmacologic expansion of donor-derived, naturally occurring CD4\u2009+\u2009Foxp3+ regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models","volume":"17","author":"Duramad","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B198","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1182\/blood-2008-06-165506","article-title":"Host natural killer T cells induce an interleukin-4\u2013dependent expansion of donor CD4\u2009+\u2009CD25\u2009+\u2009Foxp3+ T regulatory cells that protects against graft-versus-host disease","volume":"113","author":"Pillai","year":"2009","journal-title":"Blood"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2011-08-371948","article-title":"Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants","volume":"119","author":"Hongo","year":"2012","journal-title":"Blood"},{"key":"B200","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/ajt.12606","article-title":"A novel approach inducing transplant tolerance by activated invariant natural killer T cells with costimulatory blockade","volume":"14","author":"Hirai","year":"2014","journal-title":"Am J Transplant"},{"key":"B201","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1182\/blood-2016-11-752444","article-title":"Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells","volume":"129","author":"Du","year":"2017","journal-title":"Blood"},{"key":"B202","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1084\/jem.20020399","article-title":"Donor-type CD4+\u2009CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"196","author":"Hoffmann","year":"2002","journal-title":"J Exp Med"},{"key":"B203","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+\u2009CD25+\u2009regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"key":"B204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.697854","article-title":"Regulatory T cells in GVHD therapy","volume":"12","author":"Guo","year":"2021","journal-title":"Front Immunol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/ajt.12914","article-title":"Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance","volume":"14","author":"Hongo","year":"2014","journal-title":"Am J Transplant"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1182\/blood-2016-07-723015","article-title":"Tolerogenic interactions between CD8\u2009+\u2009dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts","volume":"129","author":"Hongo","year":"2017","journal-title":"Blood"},{"key":"B207","doi-asserted-by":"publisher","first-page":"6923","DOI":"10.4049\/jimmunol.181.10.6923","article-title":"CD8+ CD205+\u2009splenic dendritic cells are specialized to induce Foxp3+\u2009regulatory T cells","volume":"181","author":"Yamazaki","year":"2008","journal-title":"J Immunol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1182\/blood-2015-12-688739","article-title":"Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival","volume":"127","author":"Malard","year":"2016","journal-title":"Blood"},{"key":"B209","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/leu.2016.281","article-title":"Pre-transplant donor CD4\u2212 invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease","volume":"31","author":"Rubio","year":"2017","journal-title":"Leukemia"},{"key":"B210","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2012-01-404673","article-title":"Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival","volume":"120","author":"Rubio","year":"2012","journal-title":"Blood"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2009-03-211441","article-title":"TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors","volume":"114","author":"Kohrt","year":"2009","journal-title":"Blood"},{"key":"B212","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2017.01.069","article-title":"Increased Foxp3+\u2009Helios+ regulatory T cells and decreased acute graft-versus-host disease after allogeneic bone marrow transplantation in patients receiving sirolimus and RGI-2001, an activator of invariant natural killer T cells","volume":"23","author":"Chen","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B213","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3324\/haematol.2020.267583","article-title":"Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells","volume":"107","author":"Schmid","year":"2022","journal-title":"Haematologica"},{"key":"B214","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1182\/blood.2019001903","article-title":"High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity","volume":"135","author":"Erkers","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2024.1353803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T04:49:27Z","timestamp":1714970967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2024.1353803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":214,"alternative-id":["10.3389\/frtra.2024.1353803"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2024.1353803","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"article-number":"1353803"}}